Changes between baseline and month 24 in ETDRS level, by study endpoint
| Phenotype | Endpoint | # Patients | DR worsening | DR improving | No change | ||||||
| All | ≥3 steps | Two steps | One step | All | One step | Two steps | ≥3 steps | ||||
| A (n=87) | No CIMO | 86 (98.9%) | 17 (19.8) | 0 | 4 | 13 | 30 (34.9) | 13 | 1 | 16 | 39 (45.3) |
| CIMO | 1 (1.1%) | 0 (0.0) | 0 | 0 | 0 | 0 (0.0) | 0 | 0 | 0 | 1 (100.0) | |
| B (n=45) | No CIMO | 32 (71.1%) | 2 (6.3) | 0 | 0 | 2 | 8 (25.0) | 6 | 0 | 2 | 22 (68.8) |
| CIMO | 13 (28.9%) | 2 (15.4) | 1 | 0 | 1 | 3 (23.1) | 1 | 0 | 2 | 8 (61.5) | |
| C (n=17) | No CIMO | 12 (70.6) | 4 (33.3) | 0 | 3 | 1 | 2 (16.7) | 1 | 0 | 1 | 6 (50.0) |
| CIMO | 5 (29.4%) | 3 (60.0) | 2 | 1 | 0 | 0 (0.0) | 0 | 0 | 0 | 2 (40.0) | |
CIMO, central-involved macular oedema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study.